2-07-01 Hypervolemic hemodilution and rehydration in the early phase of ischemic stroke: Results of the multicenter Austrian hemodilution stroke trial (MAHST)

Aichner, F.; Brainin, Michael; Fazekas, Franz; Mamoli, B.; Pölz, Werner; Zeiler, K

doi:10.1016/s0022-510x(97)85201-x

Cited by 16 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One review author abstracted information from the three trials added in the 2002 update (Bornstein 1981; MAHST 1998; Rudolf 2002). Two review authors abstracted information from the three additional included trials in this 2014 update (ALIAS-Part 1 2011; ALIAS-Part 2 2013; Balcarce 1991).…”

Section: Methodsmentioning

confidence: 99%

Haemodilution for acute ischaemic stroke

Chang

Jensen

2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Haemodilution for acute ischaemic stroke

Chang

Jensen

2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Hemodilution with low-molecular-weight dextran and hydroxyethyl starch has been attempted but has not been shown to improve outcome significantly in controlled trials (135,136).…”

Section: Treatment Of Vascular Occlusive Strokementioning

confidence: 99%

Drug Therapy of Neurovascular Disease

Weinberger

Frishman²,

Terashita³

2003

Cardiology in Review

View full text Add to dashboard Cite

Recent advances in the prevention and pharmacotherapy of cerebrovascular disease have provided more favorable clinical outcomes. For the treatment of an acute ischemic stroke, the early use of thrombolytic agents can reduce the degree of brain damage while improving functional outcomes. However, trials evaluating various classes of other neuroprotective agents have not shown benefit to date. For the prevention of second stroke, the use of antiplatelet drugs, HMG-CoA reductase inhibitors, and angiotensin-converting enzyme inhibitors with a diuretic have shown benefit in reducing new events. In patients with underlying heart disease or atrial fibrillation, warfarin appears to be the drug of choice in preventing stroke. Early treatment of hemorrhagic stroke with calcium channel blockers can improve the functional outcome. Innovative therapies are now available for the treatment of migraine and vascular dementia. Primary prevention of stroke remains the optimal therapeutic strategy and includes treatment of systemic hypertension and hypercholesterolemia.

show abstract

“…22 However, treatment of the AIS patient with hypervolemic hemodilution to counter dehydration, while not harmful, has not been shown to be beneficial. 23 Based on these limited data, the authors' practice is to ensure euvolemia early by administering 2 to 3L of normal saline intravenously over the first 1 to 4 hours after presentation to all AIS patients except those with clear contraindications to modest volume loading.…”

Section: Box 2 Markers Of Potential Responsiveness To Induced Hypertementioning

confidence: 99%